The healthcare industry, often referred to as 'Big Medicine,' has become a complex web of middlemen, each with their own agenda, threatening both our wallets and our well-being. However, a potential solution lies in breaking up these powerful entities and promoting a more competitive and patient-centric system.
The Problem with Big Medicine
Big Medicine encompasses not just pharmaceutical companies but also pharmacy benefit managers (PBMs), insurance conglomerates, and wholesale drug distributors. These entities, despite their critical roles, have been driving up healthcare costs and squeezing out independent providers. The result? Americans receive average healthcare at best, yet pay the highest medical costs globally.
What many people don't realize is that six of the country's most valuable companies are from the healthcare sector, outnumbering even Big Tech. These six conglomerates generated a staggering $34 billion in profits last year alone, according to annual reports. This profit motive often takes precedence over patient care, leading to unethical practices and inflated costs.
Pharmacy Benefit Managers: A Case Study
PBMs, or pharmacy benefit managers, are a prime example of the issues within Big Medicine. The 'big three' PBMs control a staggering 80% of U.S. prescriptions and are vertically integrated with major insurance companies and pharmacies. This integration allows them to manipulate drug costs and push out independent pharmacies. For instance, the Federal Trade Commission found that these PBMs paid their affiliated pharmacies up to 7,736% more than unaffiliated competitors.
The problem extends beyond PBMs. Drug wholesalers, who control 96% of U.S. drug distribution, are also vertically integrated with medical providers, creating conflicts of interest. In one instance, a wholesaler paid $1 million to resolve allegations of paying kickbacks to healthcare providers to influence drug choices, potentially compromising patient care.
The Need for Reform
Efforts to reform PBMs have faced fierce opposition from industry groups, with even Elon Musk unwittingly playing a role in derailing progress. However, recent reforms have banned PBMs from certain practices, such as pocketing manufacturer rebates and excluding independent pharmacies from their networks.
But these reforms are not enough. Policymakers are now broadening their focus, with states like Arkansas and Tennessee passing laws to prohibit PBMs from owning pharmacies. Research suggests that such bans could reduce drug prices by over 7%, a significant step towards making healthcare more affordable.
A Potential Solution: Breaking Up Big Medicine
The Break Up Big Medicine Act, introduced by Senators Elizabeth Warren and Josh Hawley, aims to prohibit insurers, PBMs, and wholesalers from owning or controlling healthcare providers. This would effectively break up the six largest Big Medicine companies, lowering costs and promoting competition.
Research shows that this approach could have a significant impact. For example, UnitedHealthcare, the insurer arm of UnitedHealth Group, pays its affiliated Optum medical providers up to 61% more in markets where it has a substantial market share. Breaking up these companies would disrupt this unfair advantage and encourage a more level playing field.
Public support for such legislation is growing, with over 80% of voters agreeing that health insurance companies have too much control and drive up costs. Business leaders like Mark Cuban also endorse this approach.
The parallels with the Glass-Steagall Act, which separated commercial and investment banks during the Great Depression, are striking. Big Medicine poses a similar threat to the healthcare system, and breaking up these conglomerates could be a crucial step towards recovery.
In my opinion, the Break Up Big Medicine Act is a bold and necessary move to address the systemic issues within our healthcare system. While it won't solve all problems, it offers a path towards a more equitable and patient-focused healthcare landscape.
